Vascular access site complications with the use of closure devices in patients treated with platelet glycoprotein IIb/IIIa inhibitors during rescue angioplasty
- 25 October 2004
- journal article
- research article
- Published by Wiley in Catheterization and Cardiovascular Interventions
- Vol. 63 (3) , 284-289
Abstract
The objective of this study was to evaluate the effectiveness of two different closure devices in patients undergoing rescue percutaneous coronary intervention (PCI) using IIb/IIIa inhibitors and to compare it with patients undergoing elective PCI. One hundred sixty‐two patients undergoing rescue PCI treated with IIb/IIIa inhibitors underwent vascular access site closure (6 Fr Perclose, n = 92, or 6 Fr Angioseal, n = 70). Vascular complications were compared with a sex‐ and age‐matched group (n = 100) of patients undergoing manual compression after sheath removal and a similar group of patients undergoing elective PCI (n = 196). The incidence of access site complications was not significantly different between the three groups undergoing rescue PCI and was not higher than in patient receiving GP IIb/IIIa inhibitors without fibrinolysis (RR = 0.95; 95% CI = 0.88–1.01). In patients undergoing rescue PCI and receiving IIb/IIIa inhibitors, closure devices allow early sheath removal and are associated with similar outcomes compared with manual compression and elective PCI regardless of the type of closure device used. Catheter Cardiovasc Interv 2004;63:284–289.Keywords
This publication has 33 references indexed in Scilit:
- Relation of mortality of primary angioplasty during acute myocardial infarction to door-to-Thrombolysis In Myocardial Infarction (TIMI) timeThe American Journal of Cardiology, 2003
- Reduction in vascular access site bleeding in sequential abciximab coronary intervention trialsCatheterization and Cardiovascular Interventions, 2002
- Reperfusion for ST-Segment Elevation Myocardial InfarctionCirculation, 2002
- Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarctionJACC, 2002
- Comparison of Pharmacokinetics of Lanoteplase and Alteplase During Acute Myocardial InfarctionClinical Pharmacokinetics, 2002
- Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trialThe Lancet, 2001
- Pharmacokinetics and Pharmacodynamics of Tenecteplase: Results from a Phase II Study in Patients with Acute Myocardial InfarctionThe Journal of Clinical Pharmacology, 2000
- Current Clinical Use of Reteplase for ThrombolysisClinical Pharmacokinetics, 1999
- Predictors of groin complications after balloon and new-device coronary interventionThe American Journal of Cardiology, 1995
- Pharmacokinetics and fibrin specificity of alteplase during accelerated infusions in acute myocardial infarctionJACC, 1992